1. Antitumor activity of interleukin 12 in preclinical models

   • M. J. Brunda
   • Leopoldo Luistro
   • Alicia V. Palleroni

   REVIEW Pages: S16 - S21

2. Application of interleukin 12 to antitumor cytokine and gene therapy

   • T. Nishimura
   • Kazuhito Watanabe
   • Sonoko Habu

   ORIGINAL ARTICLE Pages: S27 - S34

3. In vitro model of toxin therapy targeted against murine myeloid leukemia cells

   • A. Tojo
   • Yasuo Oshima
   • Shigetaka Asano

   ORIGINAL ARTICLE Pages: S37 - S39

4. Hepatocyte growth factor in lung morphogenesis and tumor invasion: role as a mediator in epithelium-mesenchyme and tumor-stroma interactions

   • Kunio Matsumoto
   • Kazuhiko Date
   • T. Nakamura

   REVIEW Pages: S42 - S47

5. Role of glycoprotein 130 and c-Kit signaling in proliferation and differentiation of human hematopoietic progenitor cells

   • T. Nakahata
   • Xingwei Sui
   • Kohichiro Tsuji

   ORIGINAL ARTICLE Pages: S64 - S68

6. Biology and clinical potential of stem-cell factor

   • J. Glaspy
   • Mark W. Davis
   • Ian McNiece

   ORIGINAL ARTICLE Pages: S53 - S57

7. Cloning of thrombopoietin and its therapeutic potential

   • Hiroshi Miyazaki

   ORIGINAL ARTICLE Pages: S74 - S77

8. Is interleukin 3 active in anticancer drug-induced thrombocytopenia?

   • Adrian C. Newland

   REVIEW Pages: S83 - S88

9. Thrombopoietic activity of recombinant human interleukin 11 in cancer patients receiving chemotherapy

   • Michael S. Gordon

   ORIGINAL ARTICLE Pages: S96 - S98

10. Granulocyte colony-stimulating factor-induced mobilization of peripheral blood stem cells for autologous and allogeneic transplantation

    • M. Harada
    • Takanori Teshima
    • for the Fukuoka Bone Marrow Transplantation Group

    ORIGINAL ARTICLE Pages: S115 - S119

11. European School of Oncology European consensus on the use of granulocyte colony-stimulating factor: the example of breast cancer

    • Eric C. Antoine
    • D. Khayat

    REVIEW Pages: S103 - S109

12. Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes

    • N. Saijo
    • Kazuto Nishio
    • Yasutsuna Sasaki

    REVIEW Pages: S11 - S15

13. Antitumor and antimetastatic effects of interleukin 12

    • H. Fujiwara
    • Toshiyuki Hamaoka

    ORIGINAL ARTICLE Pages: S22 - S26

14. Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin’s lymphoma

    • Tiziano Barbui
    • Sergio Cortelazzo
    • A. Rossi

    ORIGINAL ARTICLE Pages: S110 - S114

15. Immunoconjugates and immunotoxins for therapy of solid tumors

    • I. Hellström
    • Pamela Trail
    • Karl Erik Hellström

    ORIGINAL ARTICLE Pages: S35 - S36

16. Costimulation of T-cell-mediated tumor immunity

    • Karl Erik Hellström
    • Lieping Chen
    • I. Hellström

    ORIGINAL ARTICLE Pages: S40 - S41

17. Differential effects of c-fms and c-kit ligands on the lineage development of the lymphohematopoietic cell line EML C1

    • Schickwann Tsai

    ORIGINAL ARTICLE Pages: S58 - S63

18. Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines

    • Naoko Kajimura
    • Hideaki Iseki
    • K. Yamaguchi

    ORIGINAL ARTICLE Pages: S48 - S52

19. Biologic effects of thrombopoietin, the Mpl ligand, and its therapeutic potential

    • Thalia Papayannopoulou

    REVIEW Pages: S69 - S73

20. Angiogenesis as a new target for cancer treatment

    • M. Ono
    • Hiroto Izumi
    • Michihiko Kuwano

    ORIGINAL ARTICLE Pages: S78 - S82

21. Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients

    • S. Kudoh
    • Toshiyuki Sawa
    • for the SDZ ILE 964 (IL-3) Study Group

    ORIGINAL ARTICLE Pages: S89 - S95

22. Effect of interleukin 11 on normal and pathological thrombopoiesis

    • M. Teramura
    • Shoko Kobayashi
    • Hideaki Mizoguchi

    ORIGINAL ARTICLE Pages: S99 - S102

23. New promising anticancer agents in development: what comes next?

    • Jaap Verweij

    ORIGINAL ARTICLE Pages: S3 - S10